| Linda Louise Cliff, | |
|
6100 Daylong Ln Ste 103, Clarksville, MD 21029-1631 | |
| (410) 531-8100 | |
| (410) 531-8900 |
| Full Name | Linda Louise Cliff |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 34 Years |
| Location | 6100 Daylong Ln Ste 103, Clarksville, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265054621 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 08405 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brighter Hope Wellness Center | 6901276419 | 2 |
News Archive
Salk Institute researchers have found that an experimental drug candidate aimed at combating Alzheimer's disease has a host of unexpected anti-aging effects in animals.
A just-released study by UT Health San Antonio and collaborating institutions shows age-related decreases in blood flow to the brain and memory loss can be modified with the drug rapamycin.
The use of next-generation gene sequencing in newborns in neonatal intensive care units (NICUs) may improve the diagnosis of rare diseases and deliver results more quickly to anxious families, according to new research in CMAJ (Canadian Medical Association Journal).
Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
› Verified 2 days ago
| Entity Name | Brighter Hope Wellness Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881192664 PECOS PAC ID: 6901276419 Enrollment ID: O20221227002179 |
News Archive
Salk Institute researchers have found that an experimental drug candidate aimed at combating Alzheimer's disease has a host of unexpected anti-aging effects in animals.
A just-released study by UT Health San Antonio and collaborating institutions shows age-related decreases in blood flow to the brain and memory loss can be modified with the drug rapamycin.
The use of next-generation gene sequencing in newborns in neonatal intensive care units (NICUs) may improve the diagnosis of rare diseases and deliver results more quickly to anxious families, according to new research in CMAJ (Canadian Medical Association Journal).
Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Linda Louise Cliff, 6100 Daylong Ln Ste 103, Clarksville, MD 21029-1631 Ph: (410) 531-8100 | Linda Louise Cliff, 6100 Daylong Ln Ste 103, Clarksville, MD 21029-1631 Ph: (410) 531-8100 |
News Archive
Salk Institute researchers have found that an experimental drug candidate aimed at combating Alzheimer's disease has a host of unexpected anti-aging effects in animals.
A just-released study by UT Health San Antonio and collaborating institutions shows age-related decreases in blood flow to the brain and memory loss can be modified with the drug rapamycin.
The use of next-generation gene sequencing in newborns in neonatal intensive care units (NICUs) may improve the diagnosis of rare diseases and deliver results more quickly to anxious families, according to new research in CMAJ (Canadian Medical Association Journal).
Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
› Verified 2 days ago
Vanessa O'connor, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6030 Daybreak Cir # A150-151, Clarksville, MD 21029 Phone: 443-698-8406 | |
Mrs. Sonya Roselle Mccollum, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 7220 Wolverton Ct, Clarksville, MD 21029 Phone: 301-346-6569 | |
Dana Stalling, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 13765 Triadelphia Mill Rd, Clarksville, MD 21029 Phone: 410-660-9997 | |
Shabana Abdullah, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 11432 Rowley Rd, Clarksville, MD 21029 Phone: 804-497-6430 | |
Ms. Sharon H Oehrelin, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 14004 Twelve Oaks Ct, Clarksville, MD 21029 Phone: 410-531-7634 |